Diclofenac for Prevention of Post-ERC Pancreatitis
ConditionCommon Bile Duct Diseases
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorKarolinska Institutet
About this trial
The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.
Eligibility criteria
Qualifiers
Patients undergoing ERCP
Disqualifiers
Decision to perform ERCP taken intraoperatively
Intolerance/allergy against NSAID
Patients taking NSAID daily
Severe cardiac fail (ASA>4)
Trial design
Treatments tested in this trial
- Diclofenac
Treatment groups
1,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Karolinska Institutet
Lead sponsor
Uppsala University
Collaborator
Source ClinicalTrials.gov